Cargando…
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC
During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2...
Autores principales: | Wang, Hung-Jung, Pochampalli, Mamata, Wang, Ling-Yu, Zou, June X, Li, Pei-Shan, Hsu, Sheng-Chieh, Wang, Bi-Juan, Huang, Shih-Han, Yang, Ping, Yang, Joy C., Chu, Cheng-Ying, Hsieh, Chia-Ling, Sung, Shian-Ying, Li, Chien-Feng, Tepper, Clifford G., Ann, David K., Gao, Allen C., Evans, Christopher P., Izumiya, Yoshihiro, Chuu, Chi-Pin, Wang, Wen-Ching, Chen, Hong-Wu, Kung, Hsing-Jien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755995/ https://www.ncbi.nlm.nih.gov/pubmed/30072740 http://dx.doi.org/10.1038/s41388-018-0414-x |
Ejemplares similares
-
RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021) -
Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023) -
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023) -
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis
por: Wu, Meng-Chen, et al.
Publicado: (2019) -
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer
por: Wu, Meng-Jen, et al.
Publicado: (2021)